Foghorn Therapeutics, Inc. (FHTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
FHTX POWR Grades
- Value is the dimension where FHTX ranks best; there it ranks ahead of 87.87% of US stocks.
- FHTX's strongest trending metric is Quality; it's been moving up over the last 177 days.
- FHTX's current lowest rank is in the Momentum metric (where it is better than 5.13% of US stocks).
FHTX Stock Summary
- The price/operating cash flow metric for FOGHORN THERAPEUTICS INC is higher than just 5.4% of stocks in our set with a positive cash flow.
- FHTX's price/sales ratio is 22.23; that's higher than the P/S ratio of 94.32% of US stocks.
- Revenue growth over the past 12 months for FOGHORN THERAPEUTICS INC comes in at 1,738.62%, a number that bests 99.36% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to FOGHORN THERAPEUTICS INC are BOLT, PSTX, BPMC, OMGA, and ALPN.
- FHTX's SEC filings can be seen here. And to visit FOGHORN THERAPEUTICS INC's official web site, go to foghorntx.com.
FHTX Valuation Summary
- In comparison to the median Healthcare stock, FHTX's price/sales ratio is 309.8% higher, now standing at 20.9.
- Over the past 27 months, FHTX's price/earnings ratio has gone up 9.7.
Below are key valuation metrics over time for FHTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| FHTX | 2023-01-20 | 20.9 | 13.5 | -3.0 | -2.7 |
| FHTX | 2023-01-19 | 20.0 | 13.0 | -2.9 | -2.6 |
| FHTX | 2023-01-18 | 20.6 | 13.4 | -3.0 | -2.7 |
| FHTX | 2023-01-17 | 21.0 | 13.6 | -3.0 | -2.7 |
| FHTX | 2023-01-13 | 23.1 | 15.0 | -3.3 | -3.0 |
| FHTX | 2023-01-12 | 23.8 | 15.5 | -3.4 | -3.1 |
FHTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- FHTX has a Quality Grade of C, ranking ahead of 42.73% of graded US stocks.
- FHTX's asset turnover comes in at 0.005 -- ranking 410th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows FHTX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.005 | 1 | -0.469 |
| 2020-12-31 | 0.003 | 1 | -0.581 |
FHTX Price Target
For more insight on analysts targets of FHTX, see our FHTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $25.67 | Average Broker Recommendation | 1.38 (Strong Buy) |
FHTX Stock Price Chart Interactive Chart >
FHTX Price/Volume Stats
| Current price | $8.51 | 52-week high | $18.12 |
| Prev. close | $8.38 | 52-week low | $5.32 |
| Day low | $8.01 | Volume | 65,500 |
| Day high | $8.62 | Avg. volume | 86,856 |
| 50-day MA | $7.12 | Dividend yield | N/A |
| 200-day MA | $10.61 | Market Cap | 355.74M |
Foghorn Therapeutics, Inc. (FHTX) Company Bio
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
Latest FHTX News From Around the Web
Below are the latest news stories about FOGHORN THERAPEUTICS INC that investors may wish to consider to help them evaluate FHTX as an investment opportunity.
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023- Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial efficacy and safety data expected in the first half of 2023 - Phase 1 dose escalation study of FHD-609, a selective degrader of BRD9, in synovial sarcoma continues to progress with initial data on safety and clinical activity expected mid-2023 - Continue to advance preclinical pipeline targeting key regulators of gene expression, including Selective BRM, ARID1B, and C |
Foghorn Therapeutics (NASDAQ:FHTX) shareholders have endured a 72% loss from investing in the stock a year agoIt's not a secret that every investor will make bad investments, from time to time. But it would be foolish to simply... |
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual MeetingCAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new preclinical data for its FHD-286 program will be presented in a poster at the 64th Annual American Society of Hematology (ASH) Meeting. The meeting will be held December 10–12, 2022 in New Orleans, LA. The data, which highlight the poten |
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx ConferenceCAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Adrian Gottschalk, President and Chief Executive Officer, will participate in the Evercore ISI HealthCONx Conference which will be held virtually on November 30, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platfo |
Morgan Stanley Keeps Their Hold Rating on Foghorn Therapeutics (FHTX)Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Foghorn Therapeutics (FHTX - Research Report) today and set a price target of $14.00. The company's shares opened today at $8.43.According to TipRanks, Purohit is an analyst with an average return of -24.4% and a 18.75% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Ascendis Pharma, and RegenXBio.Foghorn Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $24.34 and a one-year low of $7.01. Currently, Foghorn Therapeutics has an average volume of 93.41K. |
FHTX Price Returns
| 1-mo | 31.94% |
| 3-mo | 4.42% |
| 6-mo | -40.07% |
| 1-year | -39.34% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 33.39% |
| 2022 | -72.10% |
| 2021 | 12.83% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...